Q1 2026 Strides Pharma Science Ltd Earnings Call Transcript

Jul 29, 2025 / 11:00 AM GMT

Release Date Price: ₹954.55 (+3.49%)

Transcript

Key Points

Positve

Strides Pharma Science Ltd (BOM:532531) reported a strong quarter with a focus on growth, profitability, and a stronger balance sheet.
Gross margins expanded by 300 basis points, reaching a threshold of 60%, indicating improved operational efficiency.
The company achieved a significant EBITDA margin of 19.5% for the quarter, reflecting strong operating leverage.
Strides Pharma Science Ltd (BOM:532531) continues to invest in R&D programs to drive growth beyond $400 million in revenue.
The company has a robust pipeline of new products, including nasal sprays and controlled substances, which are expected to contribute to future growth.

Negative

The US market saw only a 1% year-on-year growth, with some product discontinuations impacting sales.
Access markets faced challenges due to donor funding issues, leading to lower performance in this segment.
The company experienced a temporary decline in cash flow conversion due to increased inventory levels.
Pricing challenges in the UK market were noted, although they are expected to be temporary.
Forex impacts negatively affected net debt, which could have been lower without these impacts.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SRID.NS - Strides Pharma Science Ltd
Q1 2026 Strides Pharma Science Ltd Earnings Call
Jul 29, 2025 / 11:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
In a week's time on the company's website, please know that today's discussion may be forward-looking nature and must be good relation to this pertaining to our business. After the end of this call, in case you have any further questions, please feel to, please feel free to reach out to the investor relation team. I now hand over the call to Adum to make.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
The opening comments.

--------------------------------------------------------------------------------
Unidentified_3 [3]
-----------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.